Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Glucagon-like peptide-1 (GLP-1) receptor agonists represent a class of medications originally developed for type 2 diabetes management, with select agents now FDA-approved for chronic weight management
Less common but clinically significant side effects include injection site reactions, hypoglycaemia (particularly when used with insulin or sulphonylureas), gallbladder disorders, and pancreatitis
Although the treatment landscape has expanded to include biologics and small-molecule agents, contemporary management is increasingly focused on altering the course of the disease rather than relying on symptom control alone
An intervention study in 57 healthy adults who were fed choline-deficient diets under controlled conditions found that 77% of men, 80% of postmenopausal women, and 44% of premenopausal women developed fatty liver, liver damage, and/or muscle damage (17)
.png)
US$ 29.32
US$ 24.23
US$ 22.53
US$ 23.38
